Featured Research

from universities, journals, and other organizations

In An Animal Study, Mayo Clinic Researchers Identify Ways To Delay And Increase Survival From Lou Gehrig’s Disease

Date:
December 19, 2000
Source:
Mayo Clinic
Summary:
In a study conducted using animal mice models, Mayo Clinic researchers have discovered that a modified antioxidant enzyme significantly delayed the onset and increased the survival of mice affected with familial amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

In a study conducted using animal mice models, Mayo Clinic researchers have discovered that a modified antioxidant enzyme significantly delayed the onset and increased the survival of mice affected with familial amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

The results of the study are published in the December issue of Annals of Neurology, the journal of the American Neurological Association.

ALS, or Lou Gehrig’s disease, is an uncommon, severely debilitating neurologic disorder that affects some 30,000 people in the United States at any given time. Its cause remains unknown, although in some instances of inherited ALS, a defective gene can be identified.

"This study shows for the first time that the antioxidant enzyme called catalase, when modified by the naturally-occurring polyamine, putrescine, can better penetrate the blood-brain barrier and delay the progression of this disease," says Joseph Poduslo, Ph.D., a Mayo Clinic molecular neurobiologist and the senior author of the study.

"The blood-brain barrier protects the brain from certain toxic substances and allows only a very few select substances to reach portions of the brain. Once the putrescine-modified catalase was able to reach the brain and spinal cord, it delayed the clinical course of the disease," says Dr. Poduslo. "It is hypothesized that this polyamine-modified catalase decreased the levels of hydrogen peroxide and nitric oxide, which are thought to be elevated in ALS. These findings support a direct detrimental role for free radicals in ALS.

"This is the largest increase in survival for any systemically administered drug thus far achieved in mice which have ALS that closely mimics the disease in humans," says Dr. Poduslo. "While other studies remain to be done before human clinical trials can begin, we are very encouraged by these results."

"These results represent an important extension in our understanding of this disease, and how best to proceed with research into treatments," says Eric Sorenson, M.D., a Mayo Clinic neurologist who treats patients with ALS. "While it will be some time before we are ready to begin human clinical trials, this study gives us solid information based on research in mice. Because of this, we will be able to pursue this line of research based on fact and with a much more targeted approach."

ALS causes a progressive degeneration of nerve cells in the central nervous system (brain and spinal cord). The onset is gradual and commonly localized to one part of the body initially. As the disease progresses, its effects are more widespread and may include involuntary twitching of the involved muscles. In its later stages, ALS may involve the muscles of the throat and tongue, making swallowing difficult.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "In An Animal Study, Mayo Clinic Researchers Identify Ways To Delay And Increase Survival From Lou Gehrig’s Disease." ScienceDaily. ScienceDaily, 19 December 2000. <www.sciencedaily.com/releases/2000/12/001219074938.htm>.
Mayo Clinic. (2000, December 19). In An Animal Study, Mayo Clinic Researchers Identify Ways To Delay And Increase Survival From Lou Gehrig’s Disease. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/12/001219074938.htm
Mayo Clinic. "In An Animal Study, Mayo Clinic Researchers Identify Ways To Delay And Increase Survival From Lou Gehrig’s Disease." ScienceDaily. www.sciencedaily.com/releases/2000/12/001219074938.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins